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A 68-year-old woman presented with chest pain and dyspnea and was diagnosed with a massive pulmonary embolism. Bleeding 
colon cancer was detected incidentally during anticoagulation therapy. After stabilization, she underwent surgical resection of the 
cancer with insertion of an inferior vena cava filter and was treated with rivaroxaban as antithrombotic therapy thereafter. 
Unexpectedly, thrombotic obstruction of the filter was revealed on a computed tomography scan taken in preparation for removing 
the device. After switching to warfarin, the obstruction had resolved at the 4-week follow-up examination. We discuss what to con-
sider when performing antithrombotic therapy in patients with an inferior vena cava filter. (Korean J Med 2016;90:524-527)
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INTRODUCTION
An inferior vena cava (IVC) filter can be adopted as a pre-
ventive measure for pulmonary thromboembolism in patients at 
high risk for venous thromboembolism and bleeding. Anticoagu-
lation therapy usually must be maintained after introducing these 
filters [1]. A novel oral anticoagulant can be used depending on 
the patient’s condition; however, an IVC filter can become oc-
cluded by thrombosis even under anticoagulation therapy. The ex-
act causes of or risk factors for this complication are not fully 
understood. In this case report, we describe the case of a 
68-year-old female patient who had an acute pulmonary embo-
lism and bleeding colon cancer. An IVC filter was implanted 
but totally obstructed the vessel during anticoagulation therapy 
after cancer resection. The possible mechanism and clinical im-
plications of this event are discussed.
－Dong Hyuk Park. IVC filter thrombosis during NOAC use－
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Figure 1. Chest computed tomography scan reveals an extensive 
bilateral pulmonary embolism (arrow).
Figure 2. Colonoscopy reveals a 5 cm ulcero-fungating, bleeding 
mass in the sigmoid colon.
CASE REPROT
A 68-year-old woman presented to our outpatient cardiology 
department complaining of episodes of chest pain and dyspnea 
over the past 10 days. She had experienced severe exercise-in-
duced chest pain and dyspnea while under mental stress travel-
ing across Korea. She had a history of hypercholesterolemia but 
was not taking a lipid-lowering medication. Although her vital 
signs were stable, she showed deep T wave inversion on the 
electrocardiography inferolateral leads and severe right ven-
tricular hypokinesia on echocardiography. She underwent coro-
nary angiography after hospitalization, but no significant coro-
nary artery stenosis was noted. A subsequent computed tomog-
raphy (CT) scan revealed an extensive bilateral pulmonary em-
bolism and deep vein thrombosis in the right calf vein, and she 
was started on intravenous heparin (Fig. 1). Laboratory results 
reported later did not show any hematological or immunological 
disease predisposing her to thrombosis.
She began to complain of anal bleeding on hospital day 3. 
A colonoscopy revealed a 5 cm ulcero-fungating, bleeding mass 
in the sigmoid colon that was ultimately diagnosed as adeno-
carcinoma (Fig. 2). Accordingly, heparin treatment was stopped. 
After a staging work-up and discussion with the surgical team, 
operative resection of the cancer was planned. To reduce the risk 
of thromboembolism during the period without anticoagulation, 
an IVC filter (Celect, Cook Medical Inc., Bloomington, IN, USA) 
was introduced into the infrarenal IVC on hospital day 8. She 
underwent laparoscopic resection of the sigmoid colon on hospi-
tal day 12, and 40 mg subcutaneous enoxaparin b.i.d. was start-
ed after achieving hemostasis. She was discharged after a gradu-
al recovery and has maintained self-administration of subcuta-
neous heparin.
Her condition was good at the 2-week follow-up after dis-
charge, and enoxaparin was switched to 20 mg rivaroxaban daily. 
A venous CT scan taken 10 days later and prior to removing 
the IVC filter showed a large thrombus within the filter occlud-
ing the IVC (Fig. 3A). This filter thrombus was likely an in situ 
thrombosis because it was clearly larger than the residual throm-
bus in the right calf vein. However, it was round, and the possi-
bility of migration of the deep vein thrombus could not be com-
pletely ruled out. She did not appear to be in any discomfort 
or show signs of the occlusion. We changed the rivaroxaban to 
warfarin and adjusted the dose to 3 mg daily. A follow-up ve-
nous CT scan 4 weeks later showed resolution of the thrombus, 
and the filter was removed uneventfully (Fig. 3B).
DISCUSSION
IVC filters are usually inserted when anticoagulation therapy 
is contraindicated or as an adjunct to anticoagulation. Thrombot-
－대한내과학회지: 제 90 권 제 6 호 통권 제 670 호 2016 －
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Figure 3. Venous computed tomography scan shows large throm-
bi (arrow) within the filter occluding the inferior vena cava (A). 
Follow-up imaging after warfarin therapy reveals complete reso-
lution of the thrombi (arrow) (B).
ic occlusion of these filters is reported in 2-30% of cases [2]. 
Anticoagulation after inserting an IVC filter is reportedly asso-
ciated with a lower incidence of thrombosis but no quality stud-
ies have been published on filter thrombosis [3]. Cancer is a 
well-known risk factor for thrombosis [4]. In addition, filter de-
sign and the resulting flow dynamics contribute to thombotic oc-
clusion [5]. Because the thrombosis in the present case devel-
oped during rivaroxaban therapy and resolved after admin-
istration of warfarin, drug-related factors such as poor com-
pliance or a lower response to rivaroxaban may have contributed 
to the thrombosis in this specific patient. However, we could not 
accurately determine which factors contributed to the thrombotic 
occlusion in this case.
Although many patients at risk for bleeding are ineligible for 
systemic anticoagulation therapy, our patient stably recovered 
after the cancer was resected and underwent anticoagulation 
therapy. Low molecular weight heparin (LMWH) is recommended 
in the current guidelines for patients with cancer undergoing ab-
dominal surgery or secondary prophylaxis for a venous throm-
boembolism [6]. Moreover, a meta-analysis showed that LMWH 
has better efficacy than vitamin K antagonists during long-term 
treatment of patients with cancer and an established venous 
thromboembolism.
Rivaroxaban is an oral factor Xa inhibitor with similar effi-
cacy to that of vitamin K antagonists during long-term treatment 
of pulmonary embolism with an improved benefit-risk profile [7]. 
It has similar efficacy to that of conventional anticoagulation 
therapy but a lower rate of major bleeding in patients with ve-
nous thromboembolism [8]. In addition, it does not require in-
jections or regular dose adjustments. Nevertheless, it is not equal-
ly recommended in the treatment guidelines, as there is a lack 
of sufficient data on the efficacy of this anticoagulant in patients 
with cancer and thromboembolism. Although rivaroxaban is usu-
ally prescribed at a dose of 15 mg b.i.d. in patients with an acute 
stage pulmonary embolism, we prescribed 20 mg daily in the 
present case. We used heparin in the early stages and switched 
to the novel anticoagulant 30 days after starting anticoagulation 
therapy, which was 40 days after the development of symptoms 
associated with the pulmonary embolism. At that time, we de-
cided to use 20 mg daily as the maintenance dose after the acute 
stage. The best treatment for an IVC filter thrombosis has not 
been determined but possible options include thrombolytic ther-
apy, dose escalation, or switching to another anticoagulant, add-
ing an antiplatelet agent [9], or mechanical thrombectomy [10]. 
In our case, we switched to warfarin, which was effective.
We presented a case of thrombotic occlusion of an IVC filter 
during maintenance with rivaroxaban. Multiple factors can con-
tribute to an occluded filter, and it was difficult to determine 
the major cause in our case. More studies are needed to further 
clarify if anticoagulants have different effects. Until then, drugs 
must be chosen cautiously when treating patients at high risk for 
thromboembolism.
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